Scientific Advisory Committee on Oncology Therapies - Summary of Expertise, Experience and Affiliations and Interest

Purpose of Summary

The following summarizes the information about expertise or experience, affiliations and interests relevant to the Scientific Advisory Committee on Oncology Therapies (SAC-OT) mandate declared by committee members. Health Canada considered these declarations as part of the selection process. The Health Products and Food Branch has made this summary available as part of its commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to each committee meeting, Health Canada assesses members' affiliations and interests, including direct financial interests, as they may apply to agenda items for discussion. Depending on the nature of the member's affiliations or interests, the Chair of the committee in consultation with the members, may limit the participation of a member in the meeting or ask him/her to make a verbal statement of affiliations and interests at the beginning of the meeting. Members' affiliations and interests are reviewed on an annual basis and updated as required based on changes in the status of their affiliations and interests.

In accordance with the Health Products and Food Branch Review of Regulated Products: Policy on Public Input and Guidance on Advisory Bodies, a person with a direct financial interest in the outcome of a review of a regulated product may be a member of an advisory body whose broader mandate encompasses matters of policy, management, or program development. However, such a member would not be asked to participate in any discussion, formulation of advice, or recommendations to Health Canada relating to that review.

Indicated [Sector/Perspective] and [Expertise/Experience]

Sector/perspective:

  • Health professional
  • Patient/consumer
  • Academia
  • Research

Expertise/experience:

  • Bioethics
  • Biostatistics
  • Clinical medicine
  • Clinical trial design
  • Consumer interests
  • Epidemiology
  • Immunology
  • Oncology
  • Pediatrics
  • Pharmacology
  • Radiology
  • Toxicology

1. Direct financial interests

  1. Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares or bonds, with the regulated industry

2. Indirect financial interests

  1. Within the past five years, payment from regulated industry for work done or being done, including past employment, contracts or consulting; or financial support including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria1
  2. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by the regulated industry2
  3. Within the last three years, grants or other funding from the regulated industry to any of the organizations where you are currently employed or participate in internal decision making3

3. Intellectual interests

  1. Within the last five years, any formal advice or opinion to industry, a government organization or a non-government organization on a matter of relevance to the SAC-OT
  2. Within the last five years, any published or publicly stated point of view on issues of relevance to the SAC-OT mandate
  3. Current professional or volunteer affiliations such as membership of professional societies, lobbying, public interest or advocacy groups, of relevance to the SAC-OT

4. Other

  1. Any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation

Biographies and Affiliations and Interests Summaries

Name and Indicated Sector/Perspective and Expertise Experience Summary of Responses
Alexander H.G. Paterson, MD, FRCP, FACP, MBChB (Chair) Health professional/Academia; Oncology/research 1a) Yes 2a) Yes 2b) Yes 2c)
No
3a) Yes 3b)
No
3c)
No
4a) Yes

Comments: Investments in Mutual Funds containing industrial stocks. Remunerated member of several advisory boards of the pharmaceutical industry. Honoraria and funding for travel fees received from pharmaceutical companies for giving lectures. Expert witness in a "patent protection" case in the United States. Expert on bis-phosphonates and related "bone active" therapies.

Rick Abbott, BScPharm, RPEBC Health professional; Pharmacology/research 1a)
No
2a) Yes 2b) Yes 2c) Yes 3a) Yes 3b)
No
3c)
No
4a) Yes

Comments: Unrestricted educational grants received from the pharmaceutical industry as well as grants for the conduct of a nation-wide survey and to carry out a retrospective chart audit. Funded annually by a pharmaceutical company for travel and accommodation in order to plan and facilitate meetings. Participant on advisory boards for the pharmaceutical industry. Consultant to industry on pharmaceutical related matters.

Charles A. Butts, MD, FRCPC Health professional/Academia; Oncology/research 1a)
No
2a) Yes 2b) Yes 2c) Yes 3a) Yes 3b)
No
3c) Yes 4a)
No

Comments: Received travel grants and remuneration from the pharmaceutical industry for participation in advisory boards as a member and for being a speaker. Funding received from the pharmaceutical industry for the conduct of clinical trials. President of the Canadian Association of Medical Oncologists and member of the Alberta Hospital Services Cancer Care Pharmacy and Therapeutics Committee.

Diana M. Ermel, BSc, MV/Ed Public/consumer; Consumer interests 1a)
No
2a)
No
2b)
No
2c) Yes 3a) Yes 3b) Yes 3c) Yes 4a)
No

Comments: Past president of the Canadian Breast Cancer Network (CBCN). CBCN received unencumbered funds from the pharmaceutical industry and one educational grant for the development of the Breast Cancer Wait Times in Canada Report Card 2008. Gave presentation to the Government of Canada standing committee on health regarding CDR and JODR. Member of the Canadian Cancer Action Network.

Stan Z. Gertler, MD, FRCPC Health professional/Academia; Oncology/Research 1a) Yes 2a) Yes 2b) Yes 2c) Yes 3a)
No
3b)
No
3c)
No
4a)
No

Comments: Holds shares from a pharmaceutical company. Advisory board member for several pharmaceutical companies. Received an educational grant from industry to cover partial cost of attendance to a conference. Industry/government/agency financial support for the conduct of clinical trials.

Kong E. Khoo, BSc , MD, FRCPC Health professional/Academia; Oncology/Research 1a)
No
2a)
No
2b)
No
2c) Yes 3a) Yes 3b) Yes 3c) Yes 4a)
No

Comments: Volunteer board member and Vice-Chair of the Cancer Advocacy Coalition of Canada (CACC) which receives unrestricted funds from the pharmaceutical industry. Funding received by the pharmaceutical industry for travel and accommodation to attend Academic Roundtable on Cancer Drugs. CACC publishes Annual Report Cards and articles on cancer drug access.

Kara E. Laing, MD, FRCPC Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b) Yes 2c)
No
3a) Yes 3b)
No
3c)
No
4a)
No

Comments: Remunerated by the pharmaceutical industry for giving presentations at meetings and participating in advisory boards as a member. Funding received by a pharmaceutical company for travel and accommodation fees for a meeting.

Ronald E. MacCormick, MD, FRCPC Health professional/Academia; Oncology/Epidemiology 1a)
No
2a) Yes 2b)
No
2c)
No
3a) Yes 3b)
No
3c)
No
4a)
No

Comments: Member of an advisory board for a pharmaceutical company.

Wojciech Morzycki, MD, FRCPC Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b)
No
2c)
No
3a) Yes 3b)
No
3c)
No
4a)
No

Comments: Received educational grants from pharmaceutical companies to participate in medical oncology conferences. Remunerated member of advisory boards for pharmaceutical companies in the area of lung cancer.

Lynne Nakashima, BScPharm, PharmD Health professional; Pharmacology/Oncology 1a)
No
2a) Yes 2b)
No
2c) Yes 3a)
No
3b)
No
3c) Yes 4a)
No

Comments: Gave lectures sponsored by the industry. British Columbia Cancer Agency has received grants from multiple pharmaceutical companies. Member of the Canadian Society of Hospital Pharmacists.

Scott A. North, MD, FRCPC, MHPE

Health professional/Academia; Oncology/Research

1a)
No
2a) Yes 2b)
No
2c) Yes 3a) Yes 3b)
No
3c) Yes 4a)
No

Comments: Remunerated for advice given to several advisory boards of pharmaceutical companies. Received unrestricted educational grants from pharmaceutical companies. The Alberta Cancer Board receives funding from pharmaceutical companies for the conduct of clinical trials. Volunteer member of the Kidney Cancer Canada medical advisory committee.

Lesley K. Seymour, MD, FRCPC, PhD Health professional/Academia; Oncology/Research 1a) Yes 2a) Yes 2b)
No
2c) Yes 3a)
No
3b)
No
3c)
No
4a)
No

Comments: Small pension/number of shares from a pharmaceutical company. Remunerated by the pharmaceutical industry for participating as Chair and member in advisory boards meetings. National Cancer Institute of Canada Clinical Trials Group received funding from the pharmaceutical industry to support the conduct of clinical trials.

Ian F. Tannock, MD, FRCPC, PhD Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b)
No
2c) Yes 3a) Yes 3b) Yes 3c)
No
4a)
No

Comments: Received research funding from several biotechnology and pharmaceutical companies for the conduct of clinical trials and for providing consultation. University Health Network/Princess Margaret Hospital received grants from pharmaceutical companies to conduct clinical trials and other research.

Maureen E. Trudeau, MA, MD, FRCPC Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b) Yes 2c) Yes 3a) Yes 3b)
No
3c) Yes 4a)
No

Comments: Received an award and funding to attend meetings from the pharmaceutical industry. Chaired a presentation by an outside speaker for a pharmaceutical company's event. The Odette Cancer Centre Systemic Treatment Program received funding by the pharmaceutical industry for research related to chemotherapy delivery. Volunteered advice to a pharmaceutical company regarding development of a drug, including presentation to the FDA and Health Canada. Developed cancer skin assessment tool with a pharmaceutical company and other investigators. Member of Ontario's MOH Committee to Evaluate Drugs, Oncology Subcommittee, and the Canadian Association of Medical Oncologists.

Allan Donner, PhD Academia; Biostatistics/Epidemiology 1a)
No
2a)
No
2b)
No
2c)
No
3a)
No
3b)
No
3c)
No
4a)
No
Comments: None
Justin T. Gerstle, MD, FRCSC, FACS, FAAP Health professional/Academia; Surgery/Pediatrics 1a)
No
2a)
No
2b)
No
2c)
No
3a) Yes 3b)
No
3c) Yes 4a)
No
Comments: Volunteer member of the Children's Oncology Group in the United States of America for which he participated in the design and conduct of clinical trials in renal and adrenal cancers. Volunteer work in assisting in the creation of a Paediatric Oncology Group of Ontario document to advocate for the funding of paediatric cancer care. Volunteer member of the Cancer Committee of the American Paediatric Surgery Association and presents/reviews topics on children's cancer.
Alwin Jeyakumar, MBBS, ABIM, FRCPC Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b) Yes 2c)
No
3a)
No
3b)
No
3c)
No
4a)
No
Comments: Remunerated for participation and speaking in 2 to 3 advisory board meetings per year for pharmaceutical companies. Travel and accommodations fees for a symposium funded by the pharmaceutical industry.
Christopher W. Lee, MD, FRCPC Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b) Yes 2c)
No
3a) Yes 3b)
No
3c)
No
4a)
No
Comments: Received funding from a pharmaceutical company for the conduct of a trial. Funding received from the pharmaceutical industry for travel and accommodation for advisory board meetings and forums. Remunerated member of several advisory boards for pharmaceutical companies.
Natasha B. Leighl, MD, FRCPC, MSc Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b) Yes 2c) Yes 3a) Yes 3b) Yes 3c) Yes 4a)
No
Comments: Received funding and educational grants from the pharmaceutical industry for the conduct of clinical trials. Gives several continuing medical education lectures per year. Funding received from the pharmaceutical industry for travel and accommodation for meetings. Member of the Lung Cancer Canada Board which may receive some funds from pharmaceutical companies for patient education materials. Volunteer participation in several advisory meetings for pharmaceutical companies. Has made a public statement on television in the past regarding an oncology drug. CCO/CED Advisory Committee in Ontario ; Lung Cancer Canada - Chair of medical advisory committee; Cancer Care Ontario Provincial Lung Disease Site Group.
Wendy R. Parulekar, MD, FRCPC Health professional/Academia; Oncology/Research 1a)
No
2a)
No
2b)
No
2c)
No
3a)
No
3b)
No
3c)
No
4a)
No
Comments: None
Eric Winquist, MD, FRCPC, MSc Health professional/Academia; Oncology/Research 1a)
No
2a) Yes 2b) Yes 2c) Yes 3a) Yes 3b)
No
3c)
No
4a)
No
Comments: Honoraria have been received from the pharmaceutical industry for travel and speaker's fees. Medical Director of the Cancer Clinical Research Unit in London which receives funding from the pharmaceutical industry for the conduct of clinical trials. Received consultant fees from a pharmaceutical company for advice given in response to a Health Canada Notice of Non-Compliance.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: